Bladder Cancer Podcasts Bladder Cancer RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

BISCAY trial for bladder cancer - trial design and its potential impact on clinical practice
Thomas Powles, MD, PhD from Barts Cancer Institute, London, UK discusses the BISCAY clinical trial in bladder cancer (NCT02546661). The trial looks at a group of patients with bladder cancer and next-... Author: VJHemOnc Added: 08/04/2016 (Source: Oncology Tube)
Source: Oncology Tube - August 4, 2016 Category: Cancer & Oncology Source Type: podcasts

The use of immunotherapy as a first-line therapy for bladder cancer
Thomas Powles, MD, PhD from Barts Cancer Institute, London, UK discusses a talk on immune checkpoint inhibitors in bladder cancer given at the American Society of Oncology (ASCO) 2016 Annual Meeting h... Author: VJHemOnc Added: 08/04/2016 (Source: Oncology Tube)
Source: Oncology Tube - August 4, 2016 Category: Cancer & Oncology Source Type: podcasts

Immunotherapy in non muscle invasive bladder cancer #GU16
Robert Dreicer, MD of the University of Virginia Health System discusses immunotherapy in non muscle invasive bladder cancer at ASCO GU 2016. Author: 2016_Genitourinary Added: 03/09/2016 (Source: Oncology Tube)
Source: Oncology Tube - March 9, 2016 Category: Cancer & Oncology Source Type: podcasts

Inhibiting autophagy in bladder cancer #GU16
Dr. Petros Grivas, MD at Cleveland Clinic discusses inhibiting autophagy in bladder cancer at ASCO GU 2016 Author: 2016_Genitourinary Added: 03/03/2016 (Source: Oncology Tube)
Source: Oncology Tube - March 3, 2016 Category: Cancer & Oncology Source Type: podcasts

Does treatment for prior cancer develop secondary bladder cancer #gu16
Dr. Petros Grivas, MD at Cleveland Clinic discusses if treatment for prior cancer develops secondary bladder cancer at ASCO GU 2016 Author: 2016_Genitourinary Added: 03/03/2016 (Source: Oncology Tube)
Source: Oncology Tube - March 3, 2016 Category: Cancer & Oncology Source Type: podcasts

ASCO GU 2016 Role of neoadjuvant chemotherapy and the impact of the latest randomized trials in bladder cancer
Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses the role of neoadjuvant chemotherapy and the impact of the latest randomized trials in bladder can... Author: 2016_Genitourinary Added: 01/15/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 15, 2016 Category: Cancer & Oncology Source Type: podcasts

ASCO GU 2016 Clinical trials in bladder cancer with Atezolizumab and Pembrolizumab
Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses Clinical trials in bladder cancer with Atezolizumab and Pembrolizumab at ASCO GU 2016 Author: 2016_Genitourinary Added: 01/15/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 15, 2016 Category: Cancer & Oncology Source Type: podcasts

ASCO GU 2016 Adjuvant radiation v. chemo-RT v. chemotherapy alone after radical cystectomy for locally advanced bladder cancer
Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses Adjuvant radiation v. chemo-RT v. chemotherapy alone after radical cystectomy for locally advanced... Author: 2016_Genitourinary Added: 01/15/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 15, 2016 Category: Cancer & Oncology Source Type: podcasts

Biomarker-directed, multi-drug, phase 1b trial in bladder cancer | Dr Hendrik-Tobias Arkenau at ECC 2015
At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses an open-label, biomarker-directed, multi-drug, multi-centre, m... Author: EMJ Added: 10/17/2015 (Source: Oncology Tube)
Source: Oncology Tube - October 17, 2015 Category: Cancer & Oncology Source Type: podcasts

Elizabeth R. Plimack, MD, MS - Immune Checkpoint Blockade Therapy in Bladder Cancer: Expert Perspectives on Appropriate Patient Selection and Nuances of Clinical Use
Immune Checkpoint Blockade Therapy in Bladder Cancer: Expert Perspectives on Appropriate Patient Selection and Nuances of Clinical Use (Source: PeerView CME/CE Audio Podcast - Oncology)
Source: PeerView CME/CE Audio Podcast - Oncology - October 16, 2015 Category: Cancer & Oncology Authors: Answers in CME Tags: Science, Medicine Source Type: podcasts

Updated results of a phase 1a study of anti-PDL1, MPDL3280A, in urothelial bladder cancer | Prof Thomas Powles at ASCO 2015
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles, MBBS, MRCP, MD, of Barts Cancer Institute, Queen Mary University of London, London, UK, discusses the updated re... Author: EMJ Added: 09/16/2015 (Source: Oncology Tube)
Source: Oncology Tube - September 16, 2015 Category: Cancer & Oncology Source Type: podcasts

Borealis-1™: Phase 2 trial of apatorsen plus chemotherapy in advanced bladder cancer | Dr Sumanta Pal at ASCO 2015
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sumanta K. Pal, MD, of City of Hope Comprehensive Cancer Center, Duarte, CA, discusses the results of the randomised, controlle... Author: EMJ Added: 07/24/2015 (Source: Oncology Tube)
Source: Oncology Tube - July 24, 2015 Category: Cancer & Oncology Source Type: podcasts

Gefitinib Approved for NSCLC, Atezolizumab Shrinks Bladder Tumors, New Treatment Advances in Multiple Myeloma
Laura Jones an the approval of gefitinib for EGFR-mutant lung cancer, results from a phase II study of atezolizumab in bladder cancer, and new treatment advancements in multiple myeloma. Author: onclivetv Added: 07/21/2015 (Source: Oncology Tube)
Source: Oncology Tube - July 21, 2015 Category: Cancer & Oncology Source Type: podcasts

Phase 2/3 trial of maintenance lapatinib after first-line chemotherapy in HER1/2-positive metastatic bladder cancer | Prof Thomas Powles at ASCO 2015
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles. MBBS, MRCP, MD, of Barts Cancer Institute, Queen Mary University of London, London, UK, discusses the results of... Author: EMJ Added: 07/20/2015 (Source: Oncology Tube)
Source: Oncology Tube - July 20, 2015 Category: Cancer & Oncology Source Type: podcasts

Second Line Bladder Cancer and PD-L1 - Nicholas J. Vogelzang, MD
Nicholas J. Vogelzang, MD of the University of Illinois discusses second line bladder cancer and PD-L1 antibody Author: cancergiants Added: 06/17/2015 (Source: Oncology Tube)
Source: Oncology Tube - June 17, 2015 Category: Cancer & Oncology Source Type: podcasts